These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 8244580)

  • 1. A CD16/CD30 bispecific monoclonal antibody induces lysis of Hodgkin's cells by unstimulated natural killer cells in vitro and in vivo.
    Hombach A; Jung W; Pohl C; Renner C; Sahin U; Schmits R; Wolf J; Kapp U; Diehl V; Pfreundschuh M
    Int J Cancer; 1993 Nov; 55(5):830-6. PubMed ID: 8244580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune recruitment by bispecific antibodies for the treatment of Hodgkin disease.
    da Costa L; Renner C; Hartmann F; Pfreundschuh M
    Cancer Chemother Pharmacol; 2000; 46 Suppl():S33-6. PubMed ID: 10950145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-12 increases bispecific-antibody-mediated natural killer cell cytotoxicity against human tumors.
    Sahin U; Kraft-Bauer S; Ohnesorge S; Pfreundschuh M; Renner C
    Cancer Immunol Immunother; 1996 Jan; 42(1):9-14. PubMed ID: 8625370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initiation of humoral and cellular immune responses in patients with refractory Hodgkin's disease by treatment with an anti-CD16/CD30 bispecific antibody.
    Renner C; Hartmann F; Jung W; Deisting C; Juwana M; Pfreundschuh M
    Cancer Immunol Immunother; 2000 Jun; 49(3):173-80. PubMed ID: 10881697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of heterotransplanted Hodgkin's tumors in SCID mice by a combination of human NK or T cells and bispecific antibodies.
    Renner C; Pfreundschuh M
    J Hematother; 1995 Oct; 4(5):447-51. PubMed ID: 8581383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A bispecific diabody that mediates natural killer cell cytotoxicity against xenotransplantated human Hodgkin's tumors.
    Arndt MA; Krauss J; Kipriyanov SM; Pfreundschuh M; Little M
    Blood; 1999 Oct; 94(8):2562-8. PubMed ID: 10515858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 bispecific antibody.
    Hartmann F; Renner C; Jung W; Deisting C; Juwana M; Eichentopf B; Kloft M; Pfreundschuh M
    Blood; 1997 Mar; 89(6):2042-7. PubMed ID: 9058726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-CD16/CD30 bispecific antibodies as possible treatment for refractory Hodgkin's disease.
    Hartmann F; Renner C; Jung W; Pfreundschuh M
    Leuk Lymphoma; 1998 Oct; 31(3-4):385-92. PubMed ID: 9869203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specific activation of the prodrug mitomycin phosphate by a bispecific anti-CD30/anti-alkaline phosphatase monoclonal antibody.
    Sahin U; Hartmann F; Senter P; Pohl C; Engert A; Diehl V; Pfreundschuh M
    Cancer Res; 1990 Nov; 50(21):6944-8. PubMed ID: 2170012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cure of disseminated xenografted human Hodgkin's tumors by bispecific monoclonal antibodies and human T cells: the role of human T-cell subsets in a preclinical model.
    Renner C; Bauer S; Sahin U; Jung W; van Lier R; Jacobs G; Held G; Pfreundschuh M
    Blood; 1996 Apr; 87(7):2930-7. PubMed ID: 8639913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 bispecific antibody.
    Renner C; Hartmann F; Pfreundschuh M
    Cancer Immunol Immunother; 1997; 45(3-4):184-6. PubMed ID: 9435869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells.
    Reusch U; Burkhardt C; Fucek I; Le Gall F; Le Gall M; Hoffmann K; Knackmuss SH; Kiprijanov S; Little M; Zhukovsky EA
    MAbs; 2014; 6(3):728-39. PubMed ID: 24670809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells.
    Renner C; Jung W; Sahin U; Denfeld R; Pohl C; Trümper L; Hartmann F; Diehl V; van Lier R; Pfreundschuh M
    Science; 1994 May; 264(5160):833-5. PubMed ID: 8171337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of new ricin A-chain immunotoxins with potent anti-tumor effects against human Hodgkin cells in vitro and disseminated Hodgkin tumors in SCID mice using high-affinity monoclonal antibodies directed against the CD30 antigen.
    Schnell R; Linnartz C; Katouzi AA; Schön G; Bohlen H; Horn-Lohrens O; Parwaresch RM; Lange H; Diehl V; Lemke H
    Int J Cancer; 1995 Oct; 63(2):238-44. PubMed ID: 7591211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD30-antigen-specific targeting and activation of T cells via murine bispecific monoclonal antibodies against CD3 and CD28: potential use for the treatment of Hodgkin's lymphoma.
    Pohl C; Denfeld R; Renner C; Jung W; Bohlen H; Sahin U; Hombach A; van Lier R; Schwonzen M; Diehl V
    Int J Cancer; 1993 Jul; 54(5):820-7. PubMed ID: 7686889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD30-specific AB1-AB2-AB3 internal image antibody network: potential use as anti-idiotype vaccine against Hodgkin's lymphoma.
    Pohl C; Renner C; Schwonzen M; Schobert I; Liebenberg V; Jung W; Wolf J; Pfreundschuh M; Diehl V
    Int J Cancer; 1993 May; 54(3):418-25. PubMed ID: 8389737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bispecific monoclonal antibodies directed to CD16 and to a tumor-associated antigen induce target-cell lysis by resting NK cells and by a subset of NK clones.
    Ferrini S; Prigione I; Miotti S; Ciccone E; Cantoni C; Chen Q; Colnaghi MI; Moretta L
    Int J Cancer; 1991 May; 48(2):227-33. PubMed ID: 1826900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-CD30-IL-12 antibody-cytokine fusion protein that induces IFN-gamma secretion of T cells and NK cell-mediated lysis of Hodgkin's lymphoma-derived tumor cells.
    Heuser C; Diehl V; Abken H; Hombach A
    Int J Cancer; 2003 Sep; 106(4):545-552. PubMed ID: 12845650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting properties of an anti-CD16/anti-CD30 bispecific antibody in an in vivo system.
    Renner C; Stehle I; Lee FT; Hall C; Catimel B; Nice EC; Mountain A; Rigopoulos A; Brechbiel MW; Pfreundschuh M; Scott AM
    Cancer Immunol Immunother; 2001 Apr; 50(2):102-8. PubMed ID: 11401024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Idiotype vaccine against Hodgkin's lymphoma: generation and characterization of an anti-idiotypic monoclonal antibody against the Hodgkin-associated (anti-CD 30) monoclonal antibody HRS-3.
    Pohl C; Sieber M; Diehl V; Pfreundschuh M
    Anticancer Res; 1991; 11(3):1115-24. PubMed ID: 1653553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.